You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 8, 2025

Claims for Patent: 4,544,554

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 4,544,554

Title:	Triphasic oral contraceptive
Abstract:	A method of contraception in which an estrogen and a progestogen are administered daily in a three phase sequence for 21 days is disclosed. In the first phase a combination of an estrogen and a progestogen in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 0.02-0.05 mg of 17.alpha.-ethinylestradiol and in progestogenic activity to 0.065-0.75 mg of norethindrone is administered for 5-8 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.25-1.0 mg of norethindrone for 7-11 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.35-2.0 mg of norethindrone for 3-7 days; followed by 6-8 days without administering either an estrogen or a progestogen.
Inventor(s):	Pasquale; Samuel A. (Basking Ridge, NJ)
Assignee:	Ortho Pharmaceutical Corporation (Raritan, NJ)
Application Number:	06/607,038
Patent Claims:	1. A method of contraception which comprises administering for 21 successive days to a female of childbearing age a combination of an estrogen and a progestogen in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 0.02-0.05 mg of 17.alpha.-ethinylestradiol and in progestogenic activity to 0.065-0.75 mg of norethindrone for 5-8 days; for the next 7-11 days an estrogen daily dosage equal to 0.02-0.05 mg of 17.alpha.-ethinylestradiol and in progestogenic activity to 0.250-1.0 mg of norethindrone; and for the next 3-7 days an estrogen daily dosage equal to 0.02-0.05 mg of 17.alpha.-ethinylestradiol and in progestogenic activity 0.35-2.0 mg of norethindrone; followed by 6-8 days without estrogen and progestogen administration, provided that the estrogen daily dosage is the same for each period. 2. The method of claim 1 wherein the estrogen and progestogen are administered orally and the period specified in each phase is seven days. 3. The method of claim 2 wherein the estrogen and progestogen are administered in admixture. 4. The method of claim 1 wherein the progestogen is selected from D-norgestrel, norethindrone, progesterone and D-17.beta.-acetoxy-13.beta.-ethyl-17.alpha.-ethinyl-gon-4-en-3-one oxime. 5. The method of claim 3 wherein the estrogen is selected from 17.alpha.-ethinylestradiol, estrone, estradiol and estriol. 6. The method of claim 3 wherein the estrogen is 17.alpha.-ethinylestradiol and the progestogen is norethindrone. 7. The method of claim 1 wherein the estrogen is 17.alpha.-ethinylestradiol and the progestogen is D-17.beta.-acetoxy-13.beta.-ethyl-17.alpha.-ethinyl-gon-4-en-3-one oxime. 8. The method of claim 6 wherein the estrogen daily dosage is 0.035 mg for each 7 day period and the progestogen daily dosage is 0.5 mg for the first 7 days, 0.75 mg for the second 7 days and 1.0 mg for the third 7 days. 9. The contraception method of claim 1 which comprises administering for 21 successive days to a female of childbearing age a combination of 17.alpha.-ethinylestradiol and norethindrone in a contraceptively effective daily dosage corresponding to 0.035 mg of 17.alpha.-ethinylestradiol and 0.50 mg of norethindrone for 7 days; for the next 7 days a daily dosage equal to 0.035 mg of 17.alpha.-ethinylestradiol and 0.75 mg of norethindrone; and for the next 7 days a daily dosage equal to 0.035 mg of 17.alpha.-ethinylestradiol and 1.0 mg of norethindrone; followed by 7 days without estrogen and progestogen administration. 10. The contraception method of claim 1 which comprises administering for 21 successive days to a female of childbearing age a combination of 17.alpha.-ethinylestradiol and norgestimate in a contraceptively effective daily dosage corresponding to 0.035 mg of 17.alpha.-ethinylestradiol and 0.180 mg of norgestimate for 7 days; for the next 7 days a daily dosage equal to 0.035 mg of 17.alpha.-ethinylestradiol and 0.215 mg of norgestimate; and for the next 7 days a daily dosage equal to 0.035 mg of 17.alpha.-ethinylestradiol and 0.250 mg of norgestimate; followed by 7 days without estrogen and progestogen administration.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.